Pfizer (PFE) Stops Phase 3 Trial of Sutent in Metastatic Colorectal Cancer
More News related to PFE
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX(R) (Varenicline) Compared With Placebo
- Flamel Technologies Announces Licensing Agreement with Pfizer
- Pfizer (PFE) And Medivation (MDVN) Initiate Two Phase 3 Trials Of Dimebon
- Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease
Pfizer Inc. (NYSE: PFE) announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent plus FOLFIRI versus FOLFIRI alone for the first-line treatment of metastatic colorectal cancer (CRC).
The independent Data Monitoring Committee found that the addition of sunitinib to the chemotherapy regimen FOLFIRI would be unable to demonstrate a statistically significant improvement in the primary endpoint of progression-free survival (PFS) compared to FOLFIRI alone, in this study. No new safety issues were identified.
Related Categories
FDAStocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
